Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

Journal of Clinical Oncology

Volumn 20, Issue 15, 2002, Pages 3219-3224

  Powles, Trevor ^a   Paterson, Sandy ^a   Kanis, John A ^a   McCloskey, Eugene ^a   Ashley, Sue ^a   Tidy, Alwynne ^a   Rosenqvist, Kirsi ^a   Smith, Ian ^a   Ottestad, Lars ^a   Legault, Sandra ^a   Pajunen, Marjo ^a   Nevantaus, Auli ^a   Männistö, Esa ^a   Suovuori, Anne ^a   Atula, Sari ^a   Nevalainen, Jaakko ^a   Pylkkänen, Liisa ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; PLACEBO; TAMOXIFEN;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE;

ADMINISTRATION, ORAL; ANTIMETABOLITES; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036682211     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.080     Document Type: Article

References (13)

1. The inhibition by aspirin and indomethacin of osteolytic turnout deposits and hypercalcaemia in rats with walker turnout, and its possible application to human breast cancer
2. Mechanisms of bone destruction in the development of skeletal metastases
3. Bisphosphonates: Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease
4. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
5. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
6. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
7. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial - Protocol 18 Aredia Breast Cancer Study Group
8. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
9. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
10. Bisphosphonates in the prevention of bone metastases: Current evidence
11. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
12. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial
13. Bisphosphonates and anticancer drugs